AOD 9604 5mg

AOD 9604 5mg — Modified Growth Hormone Fragment Research Peptide

AOD 9604 is a modified 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (residues 177-191), with an additional tyrosine added to the N-terminus for stability. The peptide was originally developed by researchers seeking to isolate the lipolytic effects of growth hormone from its other physiological actions. Decades of published research have characterized AOD 9604’s effects on adipose tissue metabolism and related research applications within the weight management peptides research category.

Selective Lipolytic Mechanism

Unlike full-length growth hormone, AOD 9604 has been engineered to retain only the lipolytic and fat-mobilizing effects without the broader growth-promoting, anabolic, or insulin-antagonizing actions of full GH. Research has documented that AOD 9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) without affecting growth hormone receptor-mediated signaling associated with growth. This selectivity profile makes AOD 9604 a uniquely targeted research compound.

Adipose Tissue Research

AOD 9604 has been extensively studied for effects on adipose tissue in animal models. Research has documented reduced fat mass, decreased adipocyte size, and shifts in adipose tissue gene expression patterns toward fat-mobilizing rather than fat-storing phenotypes. These effects have positioned AOD 9604 as an important research tool for adipose tissue biology and metabolic investigation.

Metabolic Research Applications

Beyond direct adipose effects, AOD 9604 has been studied for effects on metabolic parameters including glucose tolerance, insulin sensitivity, and energy expenditure. Research has examined the peptide’s effects in animal models of obesity and metabolic syndrome, with documented improvements in metabolic markers in treated animals.

Cartilage and Joint Research

More recent research has examined AOD 9604’s effects on cartilage and joint biology. Studies have documented effects on chondrocyte function, cartilage matrix production, and joint inflammation markers, broadening AOD 9604’s research applicability beyond its original metabolic focus.

Safety Profile in Research Models

A notable feature of AOD 9604 research is the peptide’s clean profile in animal studies relative to full-length growth hormone. Research has documented absence of effects on blood glucose elevation, insulin resistance, or IGF-1 elevation that characterize full GH exposure. This supports use of AOD 9604 as a controlled research tool when isolating lipolytic mechanisms from broader GH effects.

Comparison With Related Weight Management Peptides

AOD 9604 is frequently compared against incretin-based research peptides such as Semaglutide, Tirzepatide, and Retatrutide. Parallel investigations help characterize how a selective lipolytic GH fragment compares with GLP-1, GIP, and glucagon-axis compounds in matched metabolic studies.

Quality, Storage, and Compliance

Each vial of AOD 9604 5mg is manufactured to 99%+ HPLC-verified purity and supplied as a sterile lyophilized powder. Store unreconstituted vials at -20°C; reconstituted material should be refrigerated at 2–8°C. This AOD 9604 product is sold strictly for in-vitro laboratory research only — not for human consumption, diagnostic use, or any clinical application. Buyers must comply with all applicable provincial and federal regulations.